Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

18 Nov '2020
Olema Oncology Announces Pricing of Initial Public Offering
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial

Events & Presentations

Upcoming Events will be posted soon.

SEC Filings

Filing date Description Form

Notice of Exempt Offering of Securities

 D

Notice of Exempt Offering of Securities

 D

Amendment to a previously filed Notice of Exempt Offering of Securities

 D/A